Antibody Industry Trends

In recent years, the development of nanoparticles has expanded into a large range of clinical applications, including antibody conjugation and incorporation.

Over the past year, a surge of billion-dollar alliances has drawn attention to an increasingly dynamic Asian landscape, where novel antibodies, bispecifics, and antibody-drug conjugates (ADCs) are fast becoming the region’s calling cards.

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease represent an escalating global health challenge, driven by an aging population and the lack of effective disease-modifying therapies.

​The therapeutic potential of antibodies in cancer immunotherapy can be affected by their capacity to modulate T cell states within the tumor microenvironment (TME).

Monoclonal antibodies (mAbs) have become increasingly important in clinical oncology, infectious disease, and neurodegeneration. Combination antibody therapies have been picked up to overcome limitations in monotherapy, such as resistance and lower efficacy.Mechanistic Rationale for Antibody Combina

Antibody therapeutics have transformed the treatment and prevention of infectious and immune-mediated diseases. Yet most remain limited by specificity: they target a single strain, a single epitope, or a single tumor antigen. However, through the identification of conserved molecular targets and str

Antibody gene transfer is advancing the landscape of therapeutic antibody development. Amid the logistical and economic constraints of recombinant monoclonal antibody (mAb) production, nucleic acid-encoded antibody platforms (delivering DNA, mRNA, or viral vectors encoding antibody genes) are emergi

With the boom of artificial intelligence (AI), the landscape of antibody discovery and engineering is undergoing an exciting transformation. AI is increasingly embedded across all stages of the antibody development pipeline, driving rapid advances in computational biology and enabling the emergence of specialized AI-powered platforms for antibody design, discovery, and optimization.

Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.

For decades, the blood-brain barrier (BBB) was believed to be a shield that restricted efficient penetration of large antibody therapeutics from the central nervous system. This perception limited efforts to treat neurological diseases with biologics.

Monoclonal antibody (mAb) cost and accessibility challenges have fueled the development of biosimilars: biologic products designed to be copies of the reference mAb, but are often slightly different in pharmacodynamic and pharmacokinetic properties because of changes in glycosylation.

Antibody conjugates extend the therapeutic potential of monoclonal antibodies by linking them to diverse payloads, broadening their mechanisms of action.